Abstract

The need to use more and more data to generate evidence in response to new challenges in clinical medicine requires a specific response from the healthcare system. The high pace of development of medicine, the acceleration of the development of new drugs in response to the increasing needs of clinicians for treating patients leads to the need for a rapid assessment of treatment outcomes, efficacy and safety of new drugs. The development of a tool for centralized collection of data on efficacy and safety, capable of connecting as many clinical centers as possible: hospitals, private medical centers, scientific institutions — is a priority for the health system to implement these responses. An example of this type of data collection and analysis coordination system development is the 2007 Food a nd Drug Administration (FDA) Sentinel initiative.Sentinel is a national electronic system that has changed the way researchers monitor the safety of FDA-regulated medical products, including drugs, vaccines, biologics, and medical devices. Monitoring the safety of regulated products is an important part of the FDA»s mission to protect public health.This review is devoted to the history of development, organizational structure, principles of operation and demonstration of some projects of the Sentinel system. The review will consider both projects developed for application within the framework of general clinical problems (use in vulnerable groups of patients, patients with kidney diseases, etc.), and projects developed in response to the needs of researchers that have arisen in the era of the COVID-19 pandemic.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.